```
FILE 'HOME' ENTERED AT 13:16:05 ON 08 NOV 2006

=> file registry
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 13:16:14 ON 08 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     7 NOV 2006  HIGHEST RN 912617-52-8
DICTIONARY FILE UPDATES:    7 NOV 2006  HIGHEST RN 912617-52-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10525783genericbenzofuran.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
G1 C,O
G2 C,N


Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 13:16:34 FILE 'REGISTRY'
```

SAMPLE SCREEN SEARCH COMPLETED - 2459 TO ITERATE

81.3% PROCESSED 2000 ITERATIONS 3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 46206 TO 52154
PROJECTED ANSWERS: 3 TO 188

L2 3 SEA SSS SAM L1

=> d l2 scan

L2 3 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-benzofuran], 5',7'-dibromo- (9CI)
MF C14 H15 Br2 N O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L2 3 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(2-bromo-3-furanyl)-, (2'R)- (9CI)
MF C17 H17 Br N2 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 3 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Thiophenecarbonitrile, 4-(2'R)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-yl- (9CI)
MF C18 H17 N3 O S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss full
FULL SEARCH INITIATED 13:17:14 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 49545 TO ITERATE

100.0% PROCESSED 49545 ITERATIONS 226 ANSWERS
SEARCH TIME: 00.00.01

L3 226 SEA SSS FUL L1

=> d l3 scan

L3 226 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(5-chloro-3-furanyl)-, (2'R)- (9CI)
MF C17 H17 Cl N2 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L3 226 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 4'-chloro- (9CI)
MF C13 H15 Cl N2 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 226 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-(2-methyl-4-thiazolyl)-, (2'R)- (9CI)
MF C17 H19 N3 O S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 226 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-amine, N-3-pyridinyl-, (2'R)- (9CI)
MF C18 H20 N4 O

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 226 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], 5'-bromo-, (2'R)- (9CI)
MF C13 H15 Br N2 O

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 226 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Furanmethanamine, 5-(2'R)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin]-5'-yl- (9CI)
MF C18 H21 N3 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):file caplus
'FILE CAPLUS' IS NOT VALID HERE

To display more answers, enter the number of answers you would like to see. To end the display, enter "NONE", "N", "0", or "END".
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	167.82	168.03

FILE 'CAPLUS' ENTERED AT 13:17:45 ON 08 NOV 2006

FILE COVERS 1907 - 8 Nov 2006 VOL 145 ISS 20
FILE LAST UPDATED: 7 Nov 2006 (20061107/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s L3
L4          25 L3

=> s l4 and (nicotinic)
         37038 NICOTINIC
L5          25 L4 AND (NICOTINIC)

=> s l5 and (alzheim?)
         42002 ALZHEIM?
L6          11 L5 AND (ALZHEIM?)

=> d l6 1-11 ti

L6   ANSWER 1 OF 11  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of spirocyclic quinuclidinic ether derivatives as selective
     modulators of α7  nicotinic acetylcholine receptors

L6   ANSWER 2 OF 11  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of spirocyclic quinuclidinic ether derivatives as selective
     modulators of α7  nicotinic acetylcholine receptors

L6   ANSWER 3 OF 11  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   A preparation of spiro(azabicyclooctane-furopyridine) derivatives, useful
     as ligands for nicotinic acetylcholine receptors

L6   ANSWER 4 OF 11  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   A preparation of isotope-labeled spiro(azabicyclooctane-furopyridine)
     derivatives, useful as ligands for nicotinic acetylcholine
     receptor

L6   ANSWER 5 OF 11  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   α7- Nicotinic receptor agonists and statins in combination
     for the treatment of neurodegenerative diseases

L6   ANSWER 6 OF 11  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of (2'R)-5'-heterocyclylspiro[1-azabicyclo[2.2.2]octane-
     3,2'(3'H)-furo[2,3-b]pyridine] derivatives as agonists of α7
     nicotinic receptor

L6   ANSWER 7 OF 11  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of (2'R)-5'-thienylspiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-
     furo[2,3-b]pyridine] derivatives as agonists of α7  nicotinic
     receptor

L6   ANSWER 8 OF 11  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of (2'R)-5'-furylspiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-
     furo[2,3-b]pyridine] derivatives as agonists of α7  nicotinic
     receptor

L6   ANSWER 9 OF 11  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of (2'R)-5'-(3-furanyl)spiro[1-azabicyclo[2.2.2]octane]-
     3,2'(3'H)-furo[2,3-b]pyridine as a nicotinic acetylcholine
     receptor ligand

L6   ANSWER 10 OF 11  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of (2'R)-5'-(3-furanyl)spiro[1-azabicyclo[2.2.2]octane-
     3,2'(3'H)-furo[2,3-b]pyridine] as novel ligand for nicotinic
     acetylcholine receptors
```

L6 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of spiro-quinuclidines as nicotinic acetylcholine (ACh) receptor modulators

=> d l6 1-11 ti abs bib

L6 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of spirocyclic quinuclidinic ether derivatives as selective modulators of α7 nicotinic acetylcholine receptors
GI



I

Q= 

Q1= 

Q2= 

AB Compds. of formula (I) (wherein n, m = 0, 1, or 2; X = a bond, O, S, or NR1; Ar1 = a 5-membered aromatic ring, 6-membered aromatic ring, or a fused bicycloheterocycle represented by Q, Q1, or Q2; X1-X4 = N, CR2; Y1-Y3 = N, O, S, CR2; Y4 = C or N, provided that when Y4 = C, then at least one of Y1-Y3 is other than CR2; Z1-Z3 = N, O, S, CR2; R1 = H, alkyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl; R2 = H, halo, alkyl, alkoxy, alkylcarbonyl, NR3R4; R3, R4 = H, alkyl). The compds. I selectively modulate the effects of α7 nicotinic acetylcholine receptors in a mammal and are useful in treating conditions or disorders prevented by or ameliorated by an α7 nicotinic acetylcholine receptor. The above conditions or disorders include attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, Pick's disease, dementia associated with Lewy bodies, dementia associated with Down's syndrome, amyotrophic lateral sclerosis, Huntington's disease, diminished CNS function associated with traumatic brain injury, acute pain, post-surgical pain, chronic pain, inflammatory pain, neuropathic pain, infertility, need for new blood vessel growth associated with wound healing, need for new blood vessel growth associated with vascularization of skin grafts, lack of circulation, more particularly circulation around a vascular occlusion, a cognitive disorder, neurodegeneration, and schizophrenia. Thus, 5'-bromo-3'H-spiro[4-azabicyclo[2.2.2]octane-2,2'-[1]benzofuran] hydrochloride. Thus, a mixture of 5'-bromo-3'H-spiro[4-azabicyclo[2.2.2]octane-2,2'-[1]benzofuran] hydrochloride (200 mg), phenylboronic acid (276 mg), Pd2(dba)3 (Strem Chems., 12.4 mg), and 1,3-bis(2,6-diisopropylphenyl)imidazolium chloride, (Strem Chems., 95%, 18.3 mg), Na2CO3 (aqueous 2 M solution, 2 mL), ethanol (8 mL) was stirred at 80° for 15 h to give 45% 5'-phenyl-3'H-spiro[4-azabicyclo[2.2.2]octane-2,2'-[1]benzofuran]. The compds. I in vitro showed Ki of .apprx.50 nM to .apprx.100 μM in an assay of [3H]-cytisine

binding to nicotinic cholinergic receptor in rat brain membrane.

AN 2005:547268 CAPLUS

DN 143:78088

TI Preparation of spirocyclic quinuclidinic ether derivatives as selective modulators of α7 nicotinic acetylcholine receptors

IN Ji, Jianguo; Li, Tao

PA Abbott Laboratories, USA

SO U.S. Pat. Appl. Publ., 22 pp.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005137219	A1	20050623	US 2004-13193	20041215
US 7045530	B2	20060516		
PRAI US 2003-532279P	P	20031222		

OS CASREACT 143:78088; MARPAT 143:78088

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of spirocyclic quinuclidinic ether derivatives as selective modulators of α7 nicotinic acetylcholine receptors

GI



I

Q= 

Q1= 

Q2= 

AB Compds. of formula (I) (wherein n, m = 0, 1, or 2; X = a bond, O, S, or NR1; Ar1 = a 5-membered aromatic ring, 6-membered aromatic ring, or a fused bicycloheterocycle represented by Q, Q1, or Q2; X1-X4 = N, CR2; Y1-Y3 = N, O, S, CR2; Y4 = C or N, provided that when Y4 = C, then at least one of Y1-Y3 is other than CR2; Z1-Z3 = N, O, S, CR2; R1 = H, alkyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl; R2 = H, halo, alkyl, alkoxy, alkylcarbonyl, NR3R4; R3, R4 = H, alkyl). The compds. I selectively modulate the effects of α7 nicotinic acetylcholine receptors in a mammal and are useful in treating conditions or disorders prevented by or ameliorated by an α7 nicotinic acetylcholine receptor. The above conditions or disorders include attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, Pick's disease, dementia associated with Lewy bodies, dementia associated with Down's syndrome, amyotrophic lateral sclerosis, Huntington's disease, diminished CNS function associated with traumatic brain injury, acute pain, post-surgical pain, chronic pain,

inflammatory pain, neuropathic pain, infertility, need for new blood vessel growth associated with wound healing, need for new blood vessel growth associated with vascularization of skin grafts, lack of circulation, more particularly circulation around a vascular occlusion, a cognitive disorder, neurodegeneration, and schizophrenia. Thus, 5'-bromo-3'H-spiro[4-azabicyclo[2.2.2]octane-2,2'-[1]benzofuran] hydrochloride. Thus, a mixture of 5'-bromo-3'H-spiro[4-azabicyclo[2.2.2]octane-2,2'-[1]benzofuran] hydrochloride (200 mg), phenylboronic acid (276 mg), Pd2(dba)3 (Strem Chems., 12.4 mg), and 1,3-bis(2,6-diisopropylphenyl)imidazolium chloride, (Strem Chems., 95%, 18.3 mg), Na2CO3 (aqueous 2 M solution, 2 mL), ethanol (8 mL) was stirred at 80° for 15 h to give 45% 5'-phenyl-3'H-spiro[4-azabicyclo[2.2.2]octane-2,2'-[1]benzofuran]. The compds. I in vitro showed Ki of .apprx.50 nM to .apprx.100 μM in an assay of [3H]-cytisine binding to nicotinic cholinergic receptor in rat brain membrane.

AN 2005:547266 CAPLUS
DN 143:78087
TI Preparation of spirocyclic quinuclidinic ether derivatives as selective modulators of α7 nicotinic acetylcholine receptors
IN Ji, Jianguo; Li, Tao
PA USA
SO U.S. Pat. Appl. Publ., 22 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005137217	A1	20050623	US 2003-744814	20031222
	CA 2549962	AA	20050721	CA 2004-2549962	20041108
	WO 2005066168	A1	20050721	WO 2004-US37142	20041108
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1709042	A1	20061011	EP 2004-810501	20041108
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
PRAI	US 2003-744814	A	20031222		
	WO 2004-US37142	W	20041108		

OS CASREACT 143:78087; MARPAT 143:78087

L6 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
TI A preparation of spiro(azabicyclooctane-furopyridine) derivatives, useful as ligands for nicotinic acetylcholine receptors
GI



I



II



III

AB The invention relates to a preparation of spiro(azabicyclooctane-furoaryl) of formula I (Ar is a heteroaryl), useful as ligands for nicotinic acetylcholine receptors. For instance, spiro(azabicyclooctane-furopyridine) derivative II was prepared via coupling of trimethylstannylspiro(azabicyclooctane-furopyridine) derivative III with furo[3,2-b]pyridine-3-triflate. The invention compds. showed binding affinities (Ki) of less than 1000 nM.

AN 2005:409525 CAPLUS

DN 142:463709

TI A preparation of spiro(azabicyclooctane-furopyridine) derivatives, useful as ligands for nicotinic acetylcholine receptors

IN Phillips, Eifion

PA Astrazeneca Ab, Swed.; Astrazeneca Uk Limited

SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005042538	A1	20050512	WO 2004-GB4484	20041021
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004285751	A1	20050512	AU 2004-285751	20041021
	CA 2543436	AA	20050512	CA 2004-2543436	20041021
	EP 1678183	A1	20060712	EP 2004-768999	20041021
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	NO 2006002307	A	20060719	NO 2006-2307	20060522
PRAI	US 2003-512893P	P	20031021		
	WO 2004-GB4484	W	20041021		

OS MARPAT 142:463709

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
TI A preparation of isotope-labeled spiro(azabicyclooctane-furopyridine) derivatives, useful as ligands for nicotinic acetylcholine receptor
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of isotope-labeled spiro(azabicyclooctane-furopyridine) derivs. of formula I [wherein: Ar is 6-membered (un)substituted aromatic ring with 0-4 nitrogen atoms in the ring; R1 is independently at each occurrence H, alkyl, or halogen, provided that at least one occurrence of R1 comprises tritium or a halogen radioisotope], useful as ligands for nicotinic acetylcholine receptor. For instance, deuterium-labeled fluorophenylspiro(azabicyclooctane-furopyridine) derivative II was prepared from (tribromofluorophenyl)spiro(azabicyclooctane-furopyridine) derivative III and deuterium gas in the presence of palladium. The invention compds. were tested in α7 and α4 nAChR affinity assays and showed binding affinities (Ki) of less than 1000 nM.

AN 2005:300454 CAPLUS
DN 142:373816
TI A preparation of isotope-labeled spiro(azabicyclooctane-furopyridine) derivatives, useful as ligands for nicotinic acetylcholine receptor
IN Dorff, Peter; Gordon, John; Heys, John Richard; Keith, Richard A.; McCarthy, Dennis J.; Phillips, Eifion; Smith, Mark A.
PA Astrazeneca AB, Swed.; Astrazeneca UK Ltd.
SO PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005030778	A1	20050407	WO 2004-GB4116	20040924
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004276061	A1	20050407	AU 2004-276061	20040924
	CA 2538705	AA	20050407	CA 2004-2538705	20040924
	EP 1668016	A1	20060614	EP 2004-768659	20040924
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1856497	A	20061101	CN 2004-80027711	20040924
	NO 2006001819	A	20060626	NO 2006-1819	20060425
PRAI	US 2003-505731P	P	20030925		
	WO 2004-GB4116	W	20040924		

OS CASREACT 142:373816; MARPAT 142:373816

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
TI α7- Nicotinic receptor agonists and statins in combination for the treatment of neurodegenerative diseases
AB The invention discloses combinations of α7-nAChR agonists and statins, pharmaceutical compns. containing them, and methods of using them for the treatment or prophylaxis of neurol. degenerative diseases.
AN 2004:203672 CAPLUS
DN 140:229466
TI α7- Nicotinic receptor agonists and statins in combination for the treatment of neurodegenerative diseases
IN Keith, Richard
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004019947	A1	20040311	WO 2003-SE1352	20030901
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003256203	A1	20040319	AU 2003-256203	20030901
EP 1545537	A1	20050629	EP 2003-791540	20030901
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006505530	T2	20060216	JP 2004-532517	20030901
US 2005256146	A1	20051117	US 2005-525783	20050228
PRAI SE 2002-2598	A	20020902		
WO 2003-SE1352	W	20030901		

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of (2'R)-5'-heterocyclylspiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] derivatives as agonists of α7 nicotinic receptor
GI



I

AB The title compds. (I) [Ar is either a monocyclic 5-membered ring heterocycle or a bicyclic benzo-fused 5-membered ring heterocycle

connected via the 5-membered ring, having, as part of the five membered ring, one ring nitrogen atom and either one ring oxygen atom or one ring sulfur atom, said monocyclic or fused bicyclic ring heterocycle being substituted with 0, 1, or 2 substituents selected from C1-4 alkyl, C1-4 alkoxy, C1-4 halogenated alkyl, C1-4 oxygenated alkyl, C2-4 alkenyl, C2-4 alkynyl, halogen, CO2R1, COR1, cyano, NO2, (CH2)nNR1R2; n = 0-2; R1 and R2 are independently selected at each occurrence from hydrogen or C1-4 alkyl; R is a substituent selected from hydrogen, C1-4 alkyl, C1-4 halogenated alkyl, C1-4 oxygenated alkyl, or halogen] or pharmaceutically acceptable salts thereof are prepared as agonists of α7 nicotinic receptor (no data). These compds. I are useful in the treatment or prophylaxis of human diseases or conditions in which activation of α7 nicotinic receptor identify beneficial, i.e. (1) psychotic disorders or intellectual impairment disorders and (2) Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, or mania or manic depression Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapse, jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, craving, pain, and for ulcerative colitis. They are also used in a screen for the discovery of novel medicinal compds. which bind to and modulate the activity, via agonism, partial agonism, or antagonism, of the α7 nicotinic acetylcholine receptor.

AN 2003:837090 CAPLUS

DN 139:350726

TI Preparation of (2'R)-5'-heterocyclylspiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] derivatives as agonists of α7 nicotinic receptor

IN Chang, Hui-Fang; Phillips, Eifion

PA Astrazeneca AB, Swed.

SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003087104	A1	20031023	WO 2003-SE615	20030415
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2482313	AA	20031023	CA 2003-2482313	20030415
	AU 2003224546	A1	20031027	AU 2003-224546	20030415
	EP 1499616	A1	20050126	EP 2003-721209	20030415
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003009345	A	20050215	BR 2003-9345	20030415
	US 2005131003	A1	20050616	US 2003-511525	20030415
	CN 1662542	A	20050831	CN 2003-813901	20030415
	JP 2005534624	T2	20051117	JP 2003-584060	20030415
	ZA 2004008338	A	20051102	ZA 2004-8338	20041014
	NO 2004004995	A	20050118	NO 2004-4995	20041117
PRAI	SE 2002-1185	A	20020418		
	SE 2002-3606	A	20021204		
	WO 2003-SE615	W	20030415		

OS MARPAT 139:350726

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of (2'R)-5'-thienylspiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] derivatives as agonists of α7 nicotinic receptor
GI



I

AB The title compds. (I) [Ar is selected from a 2-, or 3-linked thiophene, benzo[b]thiophene or benzo[c]thiophene substituted with 0, 1, 2 or 3 substituents independently selected at each occurrence from C1-4 alkyl, C1-4 alkoxy, C1-4 halogenated alkyl, C1-4 oxygenated alkyl, C2-4 alkenyl, C2-4 alkynyl, halogen, CO2R1, COR1, cyano, NO2, (CH2)nNR1R2; n is 0, 1, or 2; R1 and R2 are independently selected at each occurrence from hydrogen or C1-4 alkyl; R is a substituent selected from hydrogen, C1-4 alkyl, C1-4 halogenated alkyl, C1-4 oxygenated alkyl, or halogen] or pharmaceutically acceptable salts thereof are prepared as agonists of α7 nicotinic receptor (no data). These compds. I are useful in the treatment or prophylaxis of human diseases or conditions in which activation of α7 nicotinic receptor identify beneficial, i.e. (1) psychotic disorders or intellectual impairment disorders and (2) Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, or mania or manic depression Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapse, jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, craving, pain, and for ulcerative colitis. They are also used in a screen for the discovery of novel medicinal compds. which bind to and modulate the activity, via agonism, partial agonism, or antagonism, of the α7 nicotinic acetylcholine receptor.
AN 2003:837089 CAPLUS
DN 139:350723
TI Preparation of (2'R)-5'-thienylspiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] derivatives as agonists of α7 nicotinic receptor
IN Chang, Hui-Fang; Li, Yan; Phillips, Eifion
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003087103	A1	20031023	WO 2003-SE614	20030415

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2482312	AA	20031023	CA 2003-2482312	20030415
AU 2003224545	A1	20031027	AU 2003-224545	20030415
EP 1499615	A1	20050126	EP 2003-721208	20030415
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009342	A	20050215	BR 2003-9342	20030415
US 2005171106	A1	20050804	US 2003-511522	20030415
CN 1659170	A	20050824	CN 2003-813782	20030415
JP 2005527588	T2	20050915	JP 2003-584059	20030415
ZA 2004008339	A	20051103	ZA 2004-8339	20041014
NO 2004004997	A	20050118	NO 2004-4997	20041117
PRAI SE 2002-1187	A	20020418		
SE 2002-3608	A	20021204		
WO 2003-SE614	W	20030415		

OS MARPAT 139:350723
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of (2'R)-5'-furylspiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] derivatives as agonists of α7 nicotinic receptor
GI



I

AB The title compds. (I) [Ar is selected from a 2-, or 3-linked furyl, benzofuryl or isobenzofuryl; substituted with 1, 2 or 3 substituents, or, when a benzofuryl or isobenzofuryl with 0, 1, 2, or 3 substituents, independently selected at each occurrence from C1-4 alkyl, C1-4 alkoxy, C1-4 halogenated alkyl, C1-4 oxygenated alkyl, C2-4 alkenyl, C2-4 alkynyl, halogen, CO2R1, COR1, cyano, NO2, (CH2)nNR1R2; n = 0-2; R1 and R2 are independently selected at each occurrence from hydrogen or C1-4 alkyl; R is a substituent selected from hydrogen, C1-4 alkyl, C1-4 halogenated alkyl, C1-4 oxygenated alkyl, or halogen] or pharmaceutically acceptable salts thereof are prepared as agonists of α7 nicotinic receptor (no data). These compds. I are useful in the treatment or prophylaxis of human diseases or conditions in which activation of α7 nicotinic receptor identify beneficial, i.e. (1) psychotic disorders or intellectual impairment disorders and (2) Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, or mania or manic depression Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapse, jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, craving, pain, and for ulcerative colitis. They are also used in a screen for the discovery of novel medicinal compds. which bind to and modulate the activity, via agonism, partial agonism, or antagonism, of the α7 nicotinic acetylcholine receptor.
AN 2003:837088 CAPLUS
DN 139:337962
TI Preparation of (2'R)-5'-furylspiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-

furo[2,3-b]pyridine] derivatives as agonists of α7 nicotinic receptor
IN Chang, Hui-Fang; Li, Yan; Phillips, Eifion
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003087102	A1	20031023	WO 2003-SE613	20030415
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2482311	AA	20031023	CA 2003-2482311	20030415
AU 2003225456	A1	20031027	AU 2003-225456	20030415
EP 1499618	A1	20050126	EP 2003-746523	20030415
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009343	A	20050215	BR 2003-9343	20030415
US 2005176745	A1	20050811	US 2003-511535	20030415
CN 1662541	A	20050831	CN 2003-813895	20030415
JP 2005533012	T2	20051104	JP 2003-584058	20030415
NO 2004004996	A	20050118	NO 2004-4996	20041117
PRAI SE 2002-1186	A	20020418		
SE 2002-3607	A	20021204		
WO 2003-SE613	W	20030415		

OS MARPAT 139:337962
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of (2'R)-5'-(3-furanyl)spiro[1-azabicyclo[2.2.2]octane]-3,2'(3'H)-furo[2,3-b]pyridine as a nicotinic acetylcholine receptor ligand
AB Title compound (I) was prepared Thus, (2'R)-5'-bromospiro[1-azabicyclo[2.2.2]octane]-3,2'(3'H)-furo[2,3-b]pyridine, 3-furylboronic acid, (PPh3)4Pd, and Na2CO3 were heated in H2O/THF/EtOH at 70° for 24h to give I. I showed acetylcholine α7 receptor binding with Ki = 0.033 nM.
AN 2003:58809 CAPLUS
DN 138:106681
TI Preparation of (2'R)-5'-(3-furanyl)spiro[1-azabicyclo[2.2.2]octane]-3,2'(3'H)-furo[2,3-b]pyridine as a nicotinic acetylcholine receptor ligand
IN Eifion, Phillips
PA USA
SO U.S. Pat. Appl. Publ., 5 pp., Cont.-in-part of U.S. Ser. No. 871,773, abandoned.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003018042	A1	20030123	US 2002-159786	20020531

	US 6569865	B2	20030527
PRAI	US 2001-367351P	P	20010601
	US 2001-871773	B1	20010601

L6 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of (2'R)-5'-(3-furanyl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] as novel ligand for nicotinic acetylcholine receptors

GI



I

AB The title compound I.2HCl, useful in the treatment or prophylaxis of psychotic disorders or intellectual impairment disorders (no biol. data given), was prepared by bromination of (R)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] followed by reacting the resulting 5'-bromo derivative with 3-furylboronic acid in the presence of Pd(PPh3)4 and Na2CO3 in H2O/EtOH/THF.

AN 2002:927434 CAPLUS

DN 138:14045

TI Preparation of (2'R)-5'-(3-furanyl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] as novel ligand for nicotinic acetylcholine receptors

IN Phillips, Eifion

PA Astrazeneca Ab, Swed.

SO PCT Int. Appl., 15 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096912	A1	20021205	WO 2002-SE1031	20020529
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2455341	AA	20021205	CA 2002-2455341	20020529
	EP 1397366	A1	20040317	EP 2002-731063	20020529
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CN 1512995	A	20040714	CN 2002-811049	20020529
	BR 2002010075	A	20040817	BR 2002-10075	20020529
	JP 2004532877	T2	20041028	JP 2003-500091	20020529
	NZ 529426	A	20050729	NZ 2002-529426	20020529
	ZA 2003008779	A	20050211	ZA 2003-8779	20031111
PRAI	US 2001-295206P	P	20010601		
	WO 2002-SE1031	W	20020529		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of spiro-quinuclidines as nicotinic acetylcholine (ACh) receptor modulators
GI



I

AB The title compds. [I; A, B = O, S, CH2, OCH2, CH2O; C = N, CR1; D = N, CR2; E = N, CR3; F = N, CR4; R1-R4 = alk(en)yl, alkynyl, (cyclo)alkyl, (cyclo)alkoxy, thioalkoxy, aryloxy, halo, CF3, cyano, amino, NO2, 5-6-membered heteroaryl, etc.; n = 1-3] or their pharmaceutically acceptable salts, useful for the treatment of disorders or diseases responsive to the activity of nicotinic ACh receptor modulators, were prepared by ketalization of quinuclidinones with catechols. Thus, spiro[benzo-1,3-dioxolane-2,3'-quinuclidine] (II) (m. 123-125°) was prepared in 3.7% yield by stirring 5.0 g quinuclidinone-HCl with 17.3 g catechol for 15 h at 200° under N. II in vitro inhibited binding of 3H-α-bungarotoxin on rat brain tissue ACh receptors with IC50 of 0.1900 μM.

AN 1998:795021 CAPLUS
DN 130:38371
TI Preparation of spiro-quinuclidines as nicotinic acetylcholine (ACh) receptor modulators
IN Peters, Dan; Olsen, Gunnar M.; Nielsen, Simon Feldbaek; Nielsen, Elsebet Ostergaard
PA Neurosearch A/s, Den.
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9854189	A1	19981203	WO 1998-DK227	19980529
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2289578	AA	19981203	CA 1998-2289578	19980529
ZA 9804637	A	19981221	ZA 1998-4637	19980529
AU 9874263	A1	19981230	AU 1998-74263	19980529
AU 744368	B2	20020221		
EP 984970	A1	20000315	EP 1998-921380	19980529
EP 984970	B1	20031119		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI				
NZ 500643	A	20011221	NZ 1998-500643	19980529
JP 2002500652	T2	20020108	JP 1999-500132	19980529
CN 1110499	B	20030604	CN 1998-805414	19980529
AT 254618	E	20031215	AT 1998-921380	19980529
US 6352995	B1	20020305	US 1999-417889	19991014

PRAI DK 1997-626 A 19970530
WO 1998-DK227 W 19980529
OS MARPAT 130:38371
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
     (FILE 'HOME' ENTERED AT 13:16:05 ON 08 NOV 2006)

     FILE 'REGISTRY' ENTERED AT 13:16:14 ON 08 NOV 2006
L1              STRUCTURE UPLOADED
L2            3 S L1
L3          226 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 13:17:45 ON 08 NOV 2006
L4           25 S L3
L5           25 S L4 AND (NICOTINIC)
L6           11 S L5 AND (ALZHEIM?)
```